EU Regs Merit Expansion To Cover Nanotech, Hybrid Products – Attorney
This article was originally published in The Gray Sheet
Executive SummaryNanotechnology device manufacturers may have to comply with as many as three regulatory schemes in Europe until a dedicated directive can be drafted, according to Belgian attorney Maarten Meulenbelt
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.